Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II single-arm trial of ISABR combined with thalidomide-based therapy for advanced melanoma after prior systemic treatment failure
ChiCTR2100043670Phase 2Not yet recruiting
- Sponsor
- Fujian Medical University Cancer Hospital
- Start
- May 2021
- Modality
- Small Molecules, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of thalidomide and toripalimab in melanoma, sponsored by Fujian Medical University Cancer Hospital. Primary endpoint: Objective response rate. Planned start May 2021; status: not yet recruiting.
02
Drugs
thalidomidetoripalimab
03
Conditions
melanoma
Beyond the preview
Go deeper on ChiCTR2100043670.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100043670.